Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Management of osteoporosis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Management of osteoporosis. | Clinical and Molecular Allergy BioMed Central Review Management of osteoporosis E Michael Lewiecki Open Access Address New Mexico Clinical Research Osteoporosis Center 300 Oak St. NE Albuquerque New Mexico 87106 USA Email E Michael Lewiecki - LEWIECKI@aol.com Corresponding author Published 14 July 2004 Received 12 May 2004 Clinical and Molecular Allergy 2004 2 9 doi 10.1186 1476-7961-2-9 Accepted 14 July 2004 This article is available from http www.clinicalmolecularallergy.cOm content 2 1 9 2004 Lewiecki licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Osteoporosis or osteopenia occurs in about 44 million Americans resulting in 1.5 million fragility fractures per year. The consequences of these fractures include pain disability depression loss of independence and increased mortality. The burden to the healthcare system in terms of cost and resources is tremendous with an estimated direct annual USA healthcare expenditure of about 17 billion. With longer life expectancy and the aging of the baby-boomer generation the number of men and women with osteoporosis or low bone density is expected to rise to over 61 million by 2020. Osteoporosis is a silent disease that causes no symptoms until a fracture occurs. Any fragility fracture greatly increases the risk of future fractures. Most patients with osteoporosis are not being diagnosed or treated. Even those with previous fractures who are at extremely high risk of future fractures are often not being treated. It is preferable to diagnose osteoporosis by bone density testing of high risk individuals before the first fracture occurs. If osteoporosis or low bone density is identified evaluation for contributing factors should be considered. Patients on long-term glucocorticoid therapy are at especially high risk for developing osteoporosis